National Institutes of HealthIssuing agency·West Virginia·via the Grants.gov Search APIWe post new health & medical research opportunities in West Virginia as agencies publish them. Get them in one email — free, and unsubscribe whenever.
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses.
The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with heterogeneity of probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33, will support studies to assess the ability of the unique patterns determined in the R61 phase to detect the improvement of probiotic responsiveness in rigorously designed mechanistic studies in relevant animal models or in human subjects.
The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful completion of Transition Milestones that need to be clearly specified in the R61 phase application.
Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-AT-24-XXX (TEMP-25413).
The award supports two phases: the R61 phase (up to 2 years) funds observational or secondary data analysis studies to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, health history) correlated with heterogeneity of probiotic clinical effects; the R33 phase funds rigorously designed mechanistic studies in relevant animal models or human subjects to assess the ability of those patterns to detect improvement of probiotic responsiveness. The combined R61/R33 should not exceed 5 years. Transition between phases is based on successful completion of specified Transition Milestones.
"20""Private institutions of higher education""01""County governments""02""City or township governments""08""Public housing authorities/Indian housing authorities""13""Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education""12""Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education""00""State governments""07""Native American tribal governments (Federally recognized)""04""Special district governments""11""Native American tribal organizations (other than Federally recognized tribal governments)""22""For profit organizations other than small businesses""23""Small businesses""25""Others (see text field entitled \"Additional Information on Eligibility\" for clarification)""05""Independent school districts""06""Public and State controlled institutions of higher education""G""Grant""ED""Education""HL""Health""NIH""HHS-NIH11""HHS-NIH11""National Institutes of Health""HHS""HHS""HHS""HHS""Department of Health and Human Services""HHS"{"id":343725,"fileName":"PAR-25-211-Full-Announcement.html","mimeType":"text/html","createdDate":"Oct 31, 2024 02:25:45 PM EDT","fileLobSize":422,"opportunityId":356925,"fileDescription":"PAR-25-211 Full Announcement Text","synopsisAttFolderId":75112}Source: Grants.gov (opportunity 356925), retrieved via the Grants.gov Search API. View the official posting , always confirm requirements and deadlines with the issuing agency.